Edition:
United States

MEI Pharma Inc (MEIP.OQ)

MEIP.OQ on NASDAQ Stock Exchange Capital Market

2.71USD
3:25pm EDT
Change (% chg)

$-0.04 (-1.45%)
Prev Close
$2.75
Open
$2.73
Day's High
$2.76
Day's Low
$2.68
Volume
15,653
Avg. Vol
72,155
52-wk High
$3.26
52-wk Low
$1.35

Chart for

About

MEI Pharma, Inc. is an oncology company. The Company is focused on the clinical development of drugs and therapies for treatment of cancer. The Company's portfolio of clinical drug candidates includes Pracinostat, ME-344 and PWT143. Pracinostat is an orally available histone deacetylase (HDAC) inhibitor indicated for the... (more)

Overall

Beta: 1.51
Market Cap(Mil.): $101.58
Shares Outstanding(Mil.): 36.94
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 81.40 16.08
EPS (TTM): -- -- --
ROI: -- 3.18 14.60
ROE: -- 4.93 14.03

BRIEF-Mei Pharma announces exclusive license agreement with Presage Biosciences for voruciclib

* Mei Pharma announces exclusive license agreement with Presage Biosciences for voruciclib, an oral, selective cdk inhibitor

Sep 05 2017

BRIEF-Helsinn group and Mei Pharma announce first patient dosed in myeloid leukemia study

* Helsinn group and Mei Pharma announce first patient dosed in pivotal phase 3 study of pracinostat and azacitidine in acute myeloid leukemia Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

Aug 02 2017

BRIEF-Helsinn Group and Mei Pharma announce first patient dosed in phase 2 dose-optimization study of pracinostat and azacitidine

* Helsinn group and Mei Pharma announce first patient dosed in phase 2 dose-optimization study of pracinostat and azacitidine in myelodysplastic syndrome

Jun 14 2017

BRIEF-Mei Pharma says one patient in ME-401 study experienced grade 3 neutropenia

* Mei Pharma announces pre-specified response rate exceeded in dose-escalation study of ME-401 in chronic lymphocytic leukemia and follicular lymphoma

May 31 2017

BRIEF-MEI Pharma Inc files for mixed shelf of up to $150 million

* MEI Pharma Inc files for mixed shelf of up to $150 million Source text for Eikon: Further company coverage:

May 04 2017

BRIEF-MEI Pharma reports Q3 loss per share $0.02

* Q3 revenue $4.5 million Source text for Eikon: Further company coverage:

May 04 2017

BRIEF-Mei Pharma announces appointment of Brian Drazba as CFO

* Mei Pharma announces appointment of Brian Drazba as Chief Financial Officer Source text for Eikon: Further company coverage:

Apr 03 2017

Earnings vs. Estimates